ISER Y9

About Syntab Therapeutics

Syntab Therapeutics is a private, preclinical-stage biotech pioneering a new approach in immuno-oncology with its proprietary Immune System Engager (ISEr) platform. These small, chemically derived molecules are designed to reprogram the innate immune system to specifically recognize and destroy cancer cells, with a lead program targeting triple-negative breast cancer. The company claims advantages in tissue penetration, manufacturing simplicity, and development speed compared to biologic therapies. Syntab is building a pipeline focused on hard-to-treat cancers and metastatic disease.

Therapeutic Areas